RxDoctor Payments Data

Steven Kopp, OD

Optometrist · Lake Havasu City, AZNPI 1841276979

Payments from drug & device makers

$2,482in general payments, 2019–2025

Across 54 payments — averaging $45.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$474
  • AbbVie$412
  • Bausch & Lomb Americas Inc.$326
  • Rxsight Inc$271
  • Glaukos Corporation$252
  • Biotissue Holdings Inc.$207
  • plus $540 from 11 others

What the payments were for

  • Speaking & faculty fees$331%
  • Food & beverage$2,44999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,482 in reported general payments places this provider in the 80th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$270,500
Medicare patients
1,333
Services billed
2,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost71$38,964
RestasisCyclosporine25$38,740
XiidraLifitegrast15$26,672
RocklatanNetarsudil Mesylat/Latanoprost18$17,887
Cyclosporine18$14,916
Latanoprost948$13,061
RhopressaNetarsudil Mesylate28$11,669
MieboPerfluorohexyloctane/Pf14$10,440
Alphagan PBrimonidine Tartrate14$8,931
Prednisolone Acetate243$7,967
Travoprost36$6,444
SimbrinzaBrinzolamide/Brimonidine Tart11$5,652
CombiganBrimonidine Tartrate/Timolol16$5,602
Brimonidine Tartrate300$3,803
Dorzolamide Hcl161$3,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$412$92,237126 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$326$37,11329 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$28$29,55646 claims
AlconSimbrinza$474$5,65211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Lake Havasu City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →